RTX-T1D

**RTX-T1D** was an investigational **red cell therapeutic** developed by **Rubius Therapeutics** for **type 1 diabetes**. Based on Rubius' RED PLATFORM, it appears to have been an **allogeneic, off-the-shelf genetically engineered red blood cell therapy** designed to induce **antigen-specific immune tolerance** in T cell-mediated autoimmune disease, rather than to replace insulin-producing cells. Publicly available information indicates the program remained **preclinical/in development** and was later **discontinued**. Specific engineered antigen payloads, final clinical formulation details, administration route, and validated human molecular target disclosures are not clearly available in the provided sources, so the precise clinical construct and target annotation remain undisclosed.

Other names

RCT therapygenetically engineered red blood cells